# To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

> **NCT06298266** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Guangdong Second Provincial General Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** infusion of GPRC5D-CD19 CAR T injection

## Key facts

- **NCT ID:** NCT06298266
- **Lead sponsor:** Guangdong Second Provincial General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03-29
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06298266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06298266, "To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06298266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*